FDA seeks comments on updated labeling guidance for biosimilar products

The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products. The guidance would replace 2018 guidance to include recommendations for labeling interchangeable products, among other changes. The agency has approved 42 biosimilar products, including four interchangeable biosimilars.